Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells

Abaza,M.S. I.

doi:10.3892/etm_00000106

Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells

Authors:
- M.S. I. Abaza
View Affiliations

Affiliations: Molecular Biology Program, Department of Biological Sciences, Faculty of Science, Kuwait University, 13060 Safat, State of Kuwait. abaza@kuc01.kuniv.edu.kw
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000106
Pages: 675-693

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The ubiquitin-proteasome pathway plays a critical role in the degradation of cellular proteins and cell cycle control. As such, dysregulating the degradation of such proteins should have profound effects on tumor growth and should cause cells to undergo apoptosis. Proteasome inhibitors display marked anticancer tendencies in hematopoietic cells; however, this activity is much less potent against solid tumor malignant cells. In addition, it can mediate toxicities such as peripheral neuropathy and can induce primary/secondary resistances. These observations prompted us to investigate whether sodium butyrate (NaB), a natural product for inducing tumor cell apoptosis that exhibits a low degree of clinical toxicity, can enhance the anticancer effects of the proteasome inhibitors MG115, MG132, PSI-1, PSI-2 and epoxomicin in human colorectal cancer. Combinations of the proteasome inhibitors and NaB markedly inhibited the proliferation of human colorectal cancer cells in a dose- and time-dependent manner, particularly compared to single treatment with NaB and the proteasome inhibitors. A combination of the proteasome inhibitors and NaB produced additive and synergistic growth inhibitory effects. The human colorectal cancer cells treated with NaB, proteasome inhibitors, and their combinations exhibited growth arrest at the G1, G2-M/S, and G1 or S/G2-M phases of the cell cycle, respectively. NaB stimulated the conversion of procaspase-3 into caspase-3 and induced the cleavage of poly(ADP-ribose) polymerase and lamin-B, which are two hallmarks of apoptosis. NaB, the proteasome inhibitor epoxomicin, and their combination stimulated the release of cytochrome-c from mitochondria, which was most likely responsible for the activation of caspase-3. Combined treatment with NaB and the proteasome inhibitors caused marked induction of apoptosis compared to single treatments of the proteasome inhibitors and NaB; the apoptotic signals were abolished by the inhibitors of caspase-3 activity. The proteasome inhibitors and their combinations with NaB counteracted the suppressive effect that was induced by NaB on the levels of p53. NaB, the proteasome inhibitors and their combinations decreased the levels of BcL2, but increased the levels of Bax, p21Waf1 and p27Kip1. Taken together, these results indicate a synergistic interaction between proteasome inhibitors and sodium butyrate that could present a new approach for the treatment of colorectal cancer.

View Figures

View References

1.	Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Bowerman B and Kurz T: Degrade to create: developmental requirements for ubiquitin-mediated proteolysis during early C. elegans embryogenesis. Development. 133:773–784. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Naujokat C and Hoffmann S: Role and function of the 20S proteasome in proliferation and apoptosis. Lab Invest. 82:965–980. 2002.
4.	Collins GA and Transey WP: The proteasome: a utility for transcription. Current Opin Genet Dev. 16:197–202. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Tylor C and Jobin C: Ubiquitin protein modification and signal transduction: Implications for inflammatory bowel diseases. Inflamm Bowel Dis. 11:1097–1107. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Asher G, Bercovich Z, Tsvetkov P, Shaul Y and Kahana C: 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell. 17:645–655. 2005.
7.	Strehl B, Seifert U, Krüger E, Heink S, Kuckelkorn U and Kloetzel PM: Interferon-γ, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev. 207:19–30. 2005.
8.	Sakai N, Sawada MT and Sawada H: Non-traditional roles of ubiquitin-proteasome system in fertilization and gametogenesis. Int J Biochem Cell Biol. 36:776–784. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Heinemeyer W, Kleinschmidt JA, Saidowsky J, Escher C and Wolf DH: Proteinase yscE, the yeast proteasome/multicatalytic-multifunctional proteinase: Mutant unravels its function in stress proteolysis and uncovers its necessity for cell survival. EMBO J. 10:555–562. 1991.
10.	Shinohara K, Tomioka M, Nakano H, Toné S, Ito H and Kawashima S: Apoptosis induction resulting from proteasome inhibition. Biochem J. 317:385–388. 1996.
11.	Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet J and Magdelenat H: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human lymphocytic leukemia lymphocytes to TNF-α initiated apoptosis. Br J Cancer. 77:1103–1107. 1998.PubMed/NCBI
12.	Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 9:1136–1144. 2003.PubMed/NCBI
13.	Teicher BA: Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res. 14:1610–1617. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 23:630–639. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 107:4907–4919. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Velazquez OC, Lederer HM and Rombeau JL: Butyrate and the colonocyte: production, absorption, metabolism, and therapeutic implications. Adv Exp Med Biol. 427:123–134. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Macfarlane GT and Gibson GR: Microbiological aspects of the production of short-chain fatty acids in the large bowel. Physiological and Clinical Aspects of Short-Chain Fatty Acids. Cambridge University Press; Cambridge: pp. 87–105. 1995
18.	Pouillart PR: Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. Life Sci. 63:1739–1760. 1998. View Article : Google Scholar : PubMed/NCBI
19.	Kruth J, Defer N and Tichonicky L: Molecular and cellular action of butyrate. C R Seances Soc Biol Fil. 186:12–25. 1992.
20.	Velazquez OC and Rombeau JL: Butyrate: potential role in colon cancer prevention and treatment. Adv Exp Med Biol. 427:169–181. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Abaza MSI, Bahman A and Al-Attiyah R: Roscovitine synergizes with conventional chemotherapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. World J Gasteroenterol. 14:5162–5175. 2008. View Article : Google Scholar
22.	Lam PK, To EW, Chan ES, Liew CT, Lung IW and King WK: In vitro modulation of head and neck cell growth by human recombinant interferon α and 13-cis-retinoic acid. Br J Biomed Sci. 58:226–229. 2001.
23.	Abaza MSI, Al-Saffar AM, Al-Sawan SM and Al-Attiyah R: c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumor Biol. 29:287–303. 2008. View Article : Google Scholar
24.	Fan XM, Wong BC, Wang WP, et al: Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer. 93:481–488. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Wilson MR: Apoptosis: unmasking the executioner. Cell Death Differ. 5:646–652. 1998. View Article : Google Scholar : PubMed/NCBI
27.	Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI
28.	Schendel SL, Montal M and Reed JC: Bcl-2 family proteins as ion-channels. Cell Death Diff. 5:372–380. 1998. View Article : Google Scholar : PubMed/NCBI
29.	Lee S, Christakos S and Small MB: Apoptosis and signal transduction: clues to a molecular mechanisms. Curr Opin Cell Biol. 5:286–289. 1993. View Article : Google Scholar : PubMed/NCBI
30.	Lopes UG, Erhardt P, Yao R and Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 272:12893–12896. 1997. View Article : Google Scholar : PubMed/NCBI
31.	Blagosklonny MV, Wu GS, Omura S and El-Deriry WS: Proteasome-dependent regulation of p21^Waf1/Cip1 expression. Biochem Biophys Res Commun. 227:564–569. 1996. View Article : Google Scholar : PubMed/NCBI
32.	Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:682–685. 1995. View Article : Google Scholar : PubMed/NCBI
33.	Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Diff. 6:303–313. 1999. View Article : Google Scholar : PubMed/NCBI
34.	Finucane DM, Wetzel-Bossy E, Waterhouse NJ, Cotter TG and Green DR: Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-XL. J Biol Chem. 274:2225–2233. 1999. View Article : Google Scholar : PubMed/NCBI
35.	Ciechanover A: Proteolysis from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 6:79–87. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Admas J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
37.	Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethsome for relapsed multiple myeloma. N Engl J Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
38.	Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 23:667–675. 2005.
39.	Hacihanefioglu A, Tarkun P and Gonullu E: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 88:219–222. 2008. View Article : Google Scholar : PubMed/NCBI
40.	Enrico O, Gabriele B, Nadia C, et al: Unexpected cardiotoxicity in haematological bortezomib-treated patients. Br J Haematol. 138:396–397. 2007. View Article : Google Scholar : PubMed/NCBI
41.	Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 24:3113–3120. 2006. View Article : Google Scholar : PubMed/NCBI
42.	Lonial S, Waller EK, Richardson PG, et al: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 106:3777–3784. 2005. View Article : Google Scholar : PubMed/NCBI
43.	Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 22:2108–2121. 2004. View Article : Google Scholar : PubMed/NCBI
44.	McConkey D and Zhu K: Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updates. 11:164–179. 2008. View Article : Google Scholar : PubMed/NCBI
45.	Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cell. 2:35–43. 1990.PubMed/NCBI
46.	Miller AA, Kurschel E, Osieka P and Schmidt CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol. 23:1283–1287. 1987. View Article : Google Scholar : PubMed/NCBI
47.	Giuliano M, Lauricella M, Calvaruso G, Carabillo M, Emanuele S, Vento R and Tesoriere G: The apoptotic effects and synergistic interaction of sodium butytrate and MG132 in human retinoblastoma Y79 cells. Cancer Res. 59:5586–5595. 1999.PubMed/NCBI
48.	Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN, Han ST, Park JW and Kwon TK: Influence of p53 and p21^waf1 expression on G₂/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J Oncol. 24:935–941. 2004.PubMed/NCBI
49.	Wu WK, Sung JY, Wu YC, Li ZJ, Yu L and Cho CH: Bone morphogenetic protein signaling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br J Pharmacol. 154:632–638. 2008. View Article : Google Scholar : PubMed/NCBI
50.	Denlinger CE, Keller MD, Mayo MW, Broad RM and Jones DR: Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg. 127:1087–1086. 2004. View Article : Google Scholar : PubMed/NCBI
51.	Abramova M, Pospelova TV, Nikulenkov FP, Hollander CM, Fornace AJ Jr and Pospelov VA: G₁/S arrest induced by deacetylase inhibitor sodium butyrate in E1A+Ras-transformed cells is mediated through down-regulation of E2F activity and stabilization of β-catenin. J Biol Chem. 281:21040–21051. 2006.
52.	Lauricella M, Calvaruso G, Giuliano M, Carabillo M, Emanuele S and Vento R: Synergistic cytotoxic interactions between butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells. Tumor Biol. 21:337–348. 2000. View Article : Google Scholar : PubMed/NCBI
53.	Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A and Omura S: Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett. 443:181–186. 1999. View Article : Google Scholar : PubMed/NCBI
54.	Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH and Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 57:5441–5446. 1997.PubMed/NCBI
55.	Timmerbeul I, Garrett-Engele CM, Kossatz U, et al: Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA. 103:14009–14014. 2006. View Article : Google Scholar : PubMed/NCBI
56.	Pandit B and Gartel AL: New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate. 70:825–833. 2010.PubMed/NCBI
57.	Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA and Anderson KC: Combination of novel proteasome inhibitor NPI-5552 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 115:834–845. 2009.PubMed/NCBI
58.	Matondo M, Bousquet-Dubouch MP, Gallay N, et al: Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: A correlation with proteasome status. Leuk Res. 34:498–506. 2009. View Article : Google Scholar : PubMed/NCBI
59.	Yuan JY, Shaham S, Ledoux S, Ellis HM and Horvitz HR: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell. 75:641–652. 1993.
60.	Nicholson DW and Thornberry NA: Caspases: killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar
61.	Talanian RV, Quinlan C, Trautz S, et al: Substrate specificities of caspase family proteases. J Biol Chem. 272:9677–9682. 1997. View Article : Google Scholar : PubMed/NCBI
62.	Fuchs E and Weber K: Intermediate filaments: structure, dynamics, function, and disease. Ann Rev Biochem. 63:345–382. 1994. View Article : Google Scholar : PubMed/NCBI
63.	Germain M, Affar EB, D’Amours D, Dixit VM, Salvesen GS and Poirier GG: Cleavage of auto-modified poly(ADP-ribose)polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem. 274:28379–28384. 1999. View Article : Google Scholar : PubMed/NCBI
64.	Cuvillier O, Rosenthal DS, Smulson ME and Spiegel S: Shingosine-1-phosphate inhibits activation of caspases that cleave poly(ADP-ribose) polymerase and lamins during Fas- and ceramide-mediated apoptosis in Jurkat lymphocytes. J Biol Chem. 273:29010–29016. 1998. View Article : Google Scholar
65.	Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
66.	Liu X, Kim CN, Yang J, Jemmerson R and Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 96:147–157. 1999.PubMed/NCBI
67.	Chandra J, Niemer I, Gilbreath J, et al: Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 92:4220–4229. 1998.PubMed/NCBI
68.	Chen YR, Wang X, Templeton D, Davis RJ and Tan TH: The role of c-jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and λ radiation. J Biol Chem. 31929–31936. 1996.
69.	Williams SA and McConkey DJ: The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 63:7338–7344. 2003.PubMed/NCBI
70.	Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin-A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 57:3697–3707. 1997.PubMed/NCBI
71.	Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH and Gandara DR: Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Sem Oncol. 31:40–46. 2004. View Article : Google Scholar : PubMed/NCBI
72.	Zhu H, Zhang L, Dong F, et al: Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene. 24:4993–4999. 2005. View Article : Google Scholar : PubMed/NCBI
73.	Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR: The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol. 2:156–162. 2000. View Article : Google Scholar : PubMed/NCBI
74.	Daly K and Shirazi-Beechey SP: Microarray analysis of butyrate-regulated genes in colonic epithelial cells. DNA Cell Biol. 25:49–62. 2006. View Article : Google Scholar : PubMed/NCBI
75.	Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr. 133(Suppl 7): 2485s–2493s. 2003.PubMed/NCBI